CONTACT BRACHYTHERAPY IN THE TREATMENT OF SUPERFICIAL NON-MELANOMA SKIN CANCER: SINGLE INSTITUTIONAL EXPERIENCE
Abstract
Introduction: Contact brachytherapy allows satisfactory treatment of superficial non-melanoma skin cancer, whether as adjuvant and/or definitive therapy. There are different techniques and different dose prescriptions in clinical practice, adapted to technical possibilities. Material and methods: 50 patients treated with contact brachytherapy for superficial non-melanoma skin cancer were analyzed, 15 of them in a postoperative and 35 in a definitive setting. Histopathologically, 40 patients had verified basal cell carcinoma and 10 had squamous cell carcinoma. High dose rate brachytherapy was performed with the GammaMed Plustm, with a radioactive Iridium192. A Leipzig-style cone contact applicator set with a diameter range of 10-45 mm was used. In 40 patients, a hypofractionated regimen was performed, with one fraction per week, with a dose of 7Gy, a total of 4 fractions, to achieve a total dose of 28Gy, over 4 weeks. A dose of 30Gy with a single fraction of 5Gy, over 6 weeks was administered to 10 patients, respectively, regardless of histological type. The dose was prescribed to a depth of 5 mm of the skin. Results: Local control was confirmed in 47 patients. In 3 patients the disease recurred 10 months after the last treatment (7Gy/4fr/28Gy). Skin redness was manifested in all patients (100%). Telangiectasia presented at the end of the treatment in 4 patients. At the first visit, all patients had reduced or completely disappeared inflammatory reactions. Conclusion: Our experience with the use of hypofractionated regimens has shown that it is a safe treatment, with easily manageable side effects.
Key words: brachytherapy, hypofractionating, skin cancer.
References
https://www.cancer.org/cancer/basal-and-squamous-cell-skin cancer/about/key-statistics.html.
2. Guix B, Finestres F, Tello J-I, et al. Treatment of skin carcinomas of the face by high-doserate brachytherapy and custom-made surface molds. Int J Radiat Oncol Biol Phys.
2000;47:95-102.
3. Smeets NW, Krekels GA, Ostertag JU, et al. Surgical excision vs Mohs’ micrographic surgery
for basal-cell carcinoma of the face: Randomised controlled trial. Lancet. 2004;364:1766–72.
4. Arenas M, Arguis M, Díez-Presa L, et al. Hypofractionated high-dose-rate plesiotherapy in
nonmelanoma skin cancer treatment. Brachytherapy. 2015;14:859-865.
5. Kalaghchi B, Esmati E, Ghalehtaki R, et al. High-dose-rate brachytherapy in treatment of nonmelanoma skin cancer of head and neck region: preliminary results of a prospective single
institution study. J Contemp Brachytherapy. 2018;10:115-122.
6. Guinot J.L., Rembielak A, Perez-Calatayud J, et al. GEC-ESTRO ACROP recommendations
in skin brachytherapy. Radiotherapy and Oncology. 2018;126:377–385.
7. Allan E, Stanton A, Pye D, et al. Fractionated high dose rate brachytherapy moulds - a precise
treatment for carcinoma of the pinna. Radiother Oncol. 1998;48:277-281.
8. Tormo A, Celada F, Rodriguez S, et al. Non-melanoma skin cancer treated with HDR
Valencia applicator: clinical outcomes. J Contemp Brachytherapy. 2014;6:167-172.
9. Gauden R, Pracy M, Avery A-M, et al. HDR brachytherapy for superficial non-melanoma skin
cancers. J Med Imaging Radiat Oncol. 2013;57:212-217.
10. Guix B, Finestres F, Tello J-I, et al. Treatment of skin carcinomas of the face by high-doserate brachytherapy and custom-made surface molds. Int J Radiat Oncol Biol Phys.
2000;47:95-102.
11. Somanchi BV, Stanton A, Webb M, et al. Hand function after high dose rate brachytherapy for
squamous cell carcinoma of the skin of the hand. Clin Oncol. 2008;20:691-697.
